Skip to main content
Journal cover image

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Publication ,  Journal Article
Amaria, RN; Menzies, AM; Burton, EM; Scolyer, RA; Tetzlaff, MT; Antdbacka, R; Ariyan, C; Bassett, R; Carter, B; Daud, A; Faries, M; Fecher, LA ...
Published in: Lancet Oncol
July 2019

Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk patient population with poor outcomes when treated with upfront surgery alone. Neoadjuvant therapy is now an active area of research for melanoma with numerous completed and ongoing trials (since 2014) with disparate designs, endpoints, and analyses under investigation. We have, therefore, established the International Neoadjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational research to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial designs and correlative analyses. Alignment and consistency of neoadjuvant trials will facilitate optimal data organisation for future regulatory review and strengthen translational research across the melanoma disease continuum.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet Oncol

DOI

EISSN

1474-5488

Publication Date

July 2019

Volume

20

Issue

7

Start / End Page

e378 / e389

Location

England

Related Subject Headings

  • Patient Selection
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Melanoma
  • Humans
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Amaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., … Long, G. V. (2019). Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol, 20(7), e378–e389. https://doi.org/10.1016/S1470-2045(19)30332-8
Amaria, Rodabe N., Alexander M. Menzies, Elizabeth M. Burton, Richard A. Scolyer, Michael T. Tetzlaff, Robert Antdbacka, Charlotte Ariyan, et al. “Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.Lancet Oncol 20, no. 7 (July 2019): e378–89. https://doi.org/10.1016/S1470-2045(19)30332-8.
Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 Jul;20(7):e378–89.
Amaria, Rodabe N., et al. “Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.Lancet Oncol, vol. 20, no. 7, July 2019, pp. e378–89. Pubmed, doi:10.1016/S1470-2045(19)30332-8.
Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 Jul;20(7):e378–e389.
Journal cover image

Published In

Lancet Oncol

DOI

EISSN

1474-5488

Publication Date

July 2019

Volume

20

Issue

7

Start / End Page

e378 / e389

Location

England

Related Subject Headings

  • Patient Selection
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Melanoma
  • Humans
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis